|
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Here we report that prostate tumor xenografts express high levels of HIF-1a and show greatly enhanced growth in response to knockdown of the E3 ligase CHIP (C-terminus of Hsp70-interacting protein).
|
31848297 |
2019 |
|
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Bone marrow adipocytes promote the Warburg phenotype in metastatic prostate tumors via HIF-1α activation.
|
27588494 |
2016 |
|
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
KLF5 loss enhances tumor angiogenesis by attenuating PI3K/AKT signaling and subsequent accumulation of HIF1α in PTEN deficient prostate tumors.
|
25896712 |
2015 |
|
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Clinical outcomes were correlated following the staining of 100 prostate tumors for HIF1α expression.
|
23342109 |
2013 |
|
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
To develop a potent strategy to increase therapeutic efficacy and reduce drug resistance in prostate cancer therapy, we combined two anti-cancer agents: T40214 (a p-Stat3 inhibitor) and JG244 (a HIF-1α inhibitor) together to treat nude mice bearing human prostate tumor (DU145) and immunocompetent mice (C57BL/6) bearing murine prostate tumor (TRAMP-C2).
|
21480310 |
2011 |
|
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
When nude mice bearing CWR-22RH human prostate tumors were treated with oral tasquinimod, there was a profound growth inhibition, associated with an up-regulation of TSP1 and a down- regulation of HIF-1 alpha protein, androgen receptor protein (AR) and glucose transporter-1 protein within the tumor tissue.
|
20470445 |
2010 |
|
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Tissue-specific expression of FoxA2 combined with Siah2-dependent HIF-1alpha availability enables a transcriptional program required for NE prostate tumor development and NE phenotype in PCa.
|
20609350 |
2010 |
|
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
A HIF-1alpha-dependent autocrine feedback loop promotes survival of serum-deprived prostate cancer cells.
|
19016246 |
2009 |
|
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
We proposed to exploit hypoxia-inducible factor (HIF)-1alpha overexpression in prostate tumours and use this transcriptional machinery to control the expression of the suicide gene cytosine deaminase (CD) through binding of HIF-1alpha to arrangements of hypoxia response elements.
|
19051213 |
2009 |
|
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
HIF-1alpha mRNA gene expression levels in improved diagnosis of early stages of prostate cancer.
|
19096962 |
2008 |
|
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
HIF-1 alpha: a key survival factor for serum-deprived prostate cancer cells.
|
18563715 |
2008 |
|
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Inhibition of HIF-1 alpha and VEGF expression by the chemopreventive bioflavonoid apigenin is accompanied by Akt inhibition in human prostate carcinoma PC3-M cells.
|
18240292 |
2008 |
|
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Since ARNT is a common dimerization partner of AhR and HIF-1alpha, we hypothesized that the AhR inhibits prostate tumor formation by competing with HIF-1alpha for ARNT, thereby limiting VEGF production.
|
18359762 |
2008 |
|
Prostatic Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
The homozygous P582S mutation in the oxygen-dependent degradation domain of HIF-1 alpha is associated with increased risk for prostate cancer.
|
16998808 |
2007 |
|
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
In the sc implanted human prostate tumors (22Rv-1) in nude mice, AN-7 significantly inhibited Ki-67, HIF-1alpha, HER-2/neu, bFGF and increased PTEN level.
|
17611019 |
2007 |
|
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Androgen-dependent gene expression of prostate-specific antigen is enhanced synergistically by hypoxia in human prostate cancer cells.
|
17426252 |
2007 |
|
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Localization of immunoreactive HIF-1alpha and HIF-2alpha in neuroendocrine cells of both benign and malignant prostate glands.
|
17562539 |
2007 |
|
Prostatic Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
Identification of hypoxia-inducible factor-1alpha (HIF-1alpha) polymorphism as a mutation in prostate cancer that prevents normoxia-induced degradation.
|
15538748 |
2005 |
|
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Herein, P-gp and HIF-1alpha expression were investigated in multicellular prostate tumor spheroids overexpressing the ROS-generating enzyme Nox-1 in comparison to the mother cell line DU-145.
|
16083877 |
2005 |
|
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
The androgen receptor is significantly associated with vascular endothelial growth factor and hypoxia sensing via hypoxia-inducible factors HIF-1a, HIF-2a, and the prolyl hydroxylases in human prostate cancer.
|
16278385 |
2005 |
|
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
Polymorphism in the hypoxia-inducible factor 1alpha gene may confer susceptibility to androgen-independent prostate cancer.
|
16205110 |
2005 |
|
Prostatic Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
Polymorphism in the hypoxia-inducible factor 1alpha gene may confer susceptibility to androgen-independent prostate cancer.
|
16205110 |
2005 |
|
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
One specimen containing a hormone-resistant prostate tumor that expressed a mutated HIF-1alpha cDNA was further microdissected into benign and tumorous regions and DNAs extracted from these regions were directly amplified by PCR and sequenced to determine whether the HIF-1alpha mutation was specific to the tumor.
|
12136249 |
2002 |
|
Prostatic Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
One specimen containing a hormone-resistant prostate tumor that expressed a mutated HIF-1alpha cDNA was further microdissected into benign and tumorous regions and DNAs extracted from these regions were directly amplified by PCR and sequenced to determine whether the HIF-1alpha mutation was specific to the tumor.
|
12136249 |
2002 |